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Background
It is critical to differentiate heparin-induced thrombocytopenia (HIT) from disseminated 
intravascular coagulation (DIC) in heparinized intensive care unit (ICU) patients with 
thrombocytopenia because the therapeutic approach differs based on the cause. We in-
vestigated the usefulness of PF4/heparin antibody tests in these patients.
Methods
A total of 127 heparinized ICU patients whose platelet counts were ＜150×10
9/L or re-
duced by ＞50% after 5-10 days of heparin therapy were enrolled. PF4/heparin antibodies 
were measured using 2 immunoassays. We assessed the probability of HIT by using 
Warkentin’s 4T’s scoring system for antibody positive patients and compared routinely 
performed coagulation test results between patients with and without antibodies to eval-
uate the ability of these tests to discriminate between HIT and DIC. 
Results
Positive results were obtained for 14 (11.0%) and 11 (8.7%) patients in the 2 assays. The 
analysis performed using the 4T’s scoring system revealed that 11 of 20 (15.7%) patients 
with antibodies in at least 1 assay had intermediate or greater probability of HIT. Patients 
without antibodies had significantly higher levels of D-dimer than those with antibodies. 
However, there were no intergroup differences in platelet counts, PT, aPTT, fibrinogen, 
DIC score, and rate of overt DIC.
Conclusion
Seropositivity for PF4/heparin antibody was 8.7-11.0% in the patients with thrombocyto-
penia, and more than a half of them had an increased probability of HIT. Among the routine 
coagulation tests, only D-dimer was informative for differentiating HIT from DIC. 
PF4/heparin antibody test is useful to ensure appropriate treatment for thrombocytopenic 
heparinized ICU patients.
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INTRODUCTION
Heparin-induced thrombocytopenia (HIT) occurs com-
monly in patients receiving heparin and it results in serious 
complications, including thrombocytopenia and thrombosis. 
HIT involves the immune-mediated formation of IgG anti-
bodies against heparin/platelet factor 4 (PF4) complexes 
bound to platelets. These antibodies can bind to the platelet 
FcγIIa receptor, activate platelets, and induce thrombin for-
mation and endothelial damage. As a result, both thrombocy-
topenia and thrombosis may develop [1-5]. Because ICU 
patients are frequently hospitalized long-term and many of 
them are post-operative, they are at high risk for venous 
thrombosis. The American College of Chest Physicians 
(ACCP) recommends heparin prophylaxis to reduce the risk 
of thrombosis in ICU patients [6]. When both thrombocyto-
penia and thrombosis develop in ICU patients receiving hep-
arin, it is critical to differentiate between HIT and DIC 
to ensure proper treatment [1].Korean J Hematol 2012;47:39-43.
40 Sang Hyuk Park, et al. 
Table 1. The Warkentin 4T’s scoring system to estimate the probability of heparin-induced thrombocytopenia.
2 points 1 point 0 point
Severity of thrombocytopenia ＞50% decrease to nadir  30-50% decrease  ＜30% decrease
＞20×10
9/L Nadir 10-20×10
9/L Nadir ＜10×10
9/L
Timing of thrombocytopenia Onset between 5-10 days ＜1 day without recent ＜5 days without recent
 (after heparin exposure)  heparin exposure  heparin exposure
＜1 day (with recent heparin Onset thrombocytopenia No heparin history
 exposure within past 15-30 days)  after day 10
Thrombosis or other sequelae New thrombosis or skin necrosis Progressive or recurrent Absent
 (e.g., skin lesions)  at injection site  thrombosis or erythematous
Post-IV heparin bolus acute systemic reaction  skin lesions at injection site
Other cause for thrombocytopenia None apparent Possible Definite
Pretest probability score: 6-8=high; 4-5=intermediate; 0-3=low.
The likelihood of HIT can be evaluated clinically using 
the Warkentin pretest scoring system, known as the “4T’s” 
[7-9]. This scoring system allows classification of patients 
into low (LR), intermediate (IR), and high risk (HR) groups 
by evaluating 4 parameters, including the severity and timing 
of thrombocytopenia, thrombosis or other findings, such 
as skin lesions, and presence of other causes of thrombocyto-
penia (Table 1). This system enables clinicians to assess the 
probability of HIT before laboratory testing. However, im-
munological detection of anti-PF4/heparin complex anti-
bodies in the patient’s serum or confirmation of platelet 
activation in normal serum after the patient’s serum is added 
is also important to confirm the diagnosis of HIT [10]. The 
gold standard for the diagnosis of HIT is the serotonin release 
assay (SRA), a radioimmunoassay that evaluates the amount 
of serotonin released when platelets are activated. However, 
this method is not routinely performed because of radiation 
hazards and technical difficulties. Heparin-induced platelet 
aggregation (HIPA) using an aggregometer is frequently used 
as a functional assay. However, a lack of inter-laboratory 
standardization and poor reproducibility are disadvantages 
of this method. Therefore, many clinical laboratories use 
simple immunological detection of antibodies against the 
PF4/heparin complex for the diagnosis of HIT [9-12]. Because 
immunoassays are relatively easy to standardize and can 
provide rapid results, several test kits have been developed. 
To date, no comprehensive study, only several case reports, 
estimating the seropositivity of PF4/Heparin antibody using 
immunoassay has been published in Korea, in particular re-
garding ICU patients in Korea who are receiving heparin 
prophylaxis.
Therefore, we have analyzed PF4/Heparin antibody sero-
positivity in thrombocytopenic ICU patients during heparin 
prophylaxis. To our knowledge, this is the first study in 
Korea to assess ICU patients for PF4/heparin antibody seropo-
sitivity and to estimate the probability of HIT in patients 
with antibody in order to evaluate the usefulness of the 
anti-PF4/Heparin antibody test.
MATERIALS AND METHODS
1. Patient selection and determination of seropositivity of 
PF4/heparin antibody
A total of 127 ICU patients treated with heparin prophy-
laxis whose platelet counts were ＜150×10
9/L and/or were 
reduced by more than 50% at 5-10 days after initiation 
of heparin therapy from January 2011 to May 2011 were 
enrolled in this study. All patients and/or family members 
received informed consent about this study from the 
clinician. The plasma samples for the patients meeting the 
above conditions were collected and cryopreserved at -70
oC 
for retrospective analysis. The samples were thawed at the 
time of the test. Two kinds of immunoassay for the detection 
of anti-PF4/heparin antibody (IgG, IgA, and IgM), Assera-
chrom HPIA (Diagnostica Stago, Asnières, France) and 
HemosIL HIT-Ab (Instrumentation Laboratory, Milan, Italy) 
assay, were performed simultaneously for each sample. These 
2 immunoassays were performed according to the manu-
facturers’ instructions. Based on the manufacturers’ recom-
mendations, cutoff values for the determination of a positive 
result were defined as an optical density of 0.304 for the 
Asserachrom HPIA assay and a level of 1 U/mL for the 
HemosIL HIT-Ab assay. No samples were duplicated, and 
positivity was not confirmed by a repeat test. The seroposi-
tivity of anti-PF4/Heparin antibody was determined accord-
ing to these results, and the clinical likelihood of HIT was 
evaluated using Warkentin 4T’s scoring system for patients 
with antibody in at least 1 of the 2 assays.
2. Evaluation of usefulness of commonly performed coagu-
lation tests to discriminate between DIC and HIT
Five commonly used coagulation tests - platelet count, 
prothrombin time (PT), activated partial thromboplastin time 
(aPTT), D-dimer, and fibrinogen level - were performed 
in all the enrolled patients. For PT and aPTT, Thromborel 
S (Siemens Healthcare Diagnostics, GmbH, Marburg, Ger-
many) and Dade Actin FSL Activated PTT Reagent (Siemens 
Healthcare Diagnostics) were used as reagents, respectively. 
For fibrinogen and D-dimer, Dade Thrombin Reagent Korean J Hematol 2012;47:39-43.
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Table 2. The ISTH 2001 DIC scoring system for the diagnosis of overt DIC.
0 point 1 point 2 points 3 points
Platelet count (×10
9/L) ＞100 50-100 ＜50
Fibrin-related marker (D-dimer, μg/L) ＜500 500-800 ＞800
PT (sec)  Not prolonged Prolongation of PT 3-6 sec Prolongation of PT ＞6 sec
Fibrinogen (g/L)  ≥1 ≤1
Abbreviations: PT, prothrombin time; DIC, disseminated intravascular coagulation; ISTH, International Society of Thrombosis and Hemostasis.
Overt DIC: ≥5 points.
Table 3. The results of 2 ELISA tests for detecting anti-PF4/heparin 
antibodies in 127 heparin-treated ICU patients with thrombocy-
topenic events.
HemosIL HIT-Ab
Asserachrom HPIA
Negative Positive Total
Negative 107     9 116
Positive      6   5    11
Total 113 14 127
Twenty (15.7%) patients showed positivity in at least 1 of the 2 
assays.
Abbreviation: ICU, intensive care unit.
(Siemens Healthcare Diagnostics) and INNOVANCE D-dim-
er (Siemens Healthcare Diagnostics) were used as reagents. 
All the tests were performed using an automatic coagulation 
analyzer (Sysmex CA-7000, Siemens Healthcare Diagnos-
tics). Using these data, the DIC score was calculated according 
to the DIC scoring system (Table 2) suggested by Interna-
tional Society of Thrombosis and Hemostasis (ISTH) in 2001 
[13]. Additionally, the rate of overt DIC, which was defined 
as DIC score ≥5, was analyzed. Based on all data, results 
of investigated parameters (platelet counts, PT, aPTT, D-dim-
er, fibrinogen, DIC score, and the percentage of overt DIC) 
were compared between patients with antibody in at least 
1 of the 2 assays and those without antibody to evaluate 
the usefulness of these tests as criteria to discriminate be-
tween DIC and HIT.
3. Statistical analysis
The Mann-Whitney U test was performed for the compar-
ison of platelet counts, PT, aPTT, D-dimer, fibrinogen, and 
DIC score between patients with PF4/heparin antibody and 
those without antibody. The Chi-square test was performed 
for the comparison of the percentage of overt DIC between 
patients with antibody and those without antibody. For all 
analyses, tests were two-tailed, and P≤0.05 was considered 
statistically significant. All calculations were performed us-
ing SPSS 13.0.1 for Windows (SPSS Inc, Chicago, IL, USA).
RESULTS
1. Seropositivity of PF4/heparin antibody
Among a total of 127 patients, 14 (11.0%) and 11 (8.7%) 
showed positivity in Asserachrom HPIA and HemosIL HIT- 
Ab assays, respectively. The concordance rate between these 
2 assays was 88.2%. Five (3.9%) patients showed positivity 
in both assays, and 20 (15.7%) patients showed positivity 
in at least 1 of the 2 assays. Among the 20 patients with 
antibody positivity in at least 1 of the 2 assays, 11 (55.0%) 
were categorized as intermediate of high risk for HIT based 
on scores of ≥4 by Warkentin 4T’s scoring system (Table 3).
2. Evaluation of usefulness of commonly performed coagu-
lation tests to discriminate between DIC and HIT
Patients without PF4/heparin antibody showed signifi-
cantly higher median D-dimer levels than those with anti-
body in at least 1 of the 2 assays (4.17×10
3 vs. 2.45×10
3 
μg/L, P=0.016). However, there were no significant differ-
ences in median platelet counts (56.0 vs. 62.5×10
9/L, 
P=0.460), median PT (15.2 vs. 14.4 sec, P=0.853), aPTT (40.7 
vs. 42.1 sec, P=0.789), fibrinogen (2.62 vs. 2.00 g/L, P=0.142), 
DIC score (4.0 vs. 3.5 scores, P=0.495), or the percentage 
of overt DIC (43.0% vs. 35.0%, P=0.506) between patients 
without antibody and those with antibody in at least 1 of 
the 2 assays (Table 4).
DISCUSSION
HIT can result in severe complications, including throm-
bosis, if it occurs in ICU patients in whom heparin is used 
as prophylaxis to reduce the risk of venous thromboem-
bolism. Therefore, early recognition of HIT is deemed 
essential. In cases where HIT is suspected, laboratory evalua-
tion for the diagnosis of HIT should be initiated promptly. 
The Warkentin 4T’s scoring system for the assessment of 
clinical likelihood of HIT has demonstrated a negative pre-
dictive value of 100%, so that when the score is less than 
4, we can exclude the possibility of HIT. However, for the 
confirmation of HIT, the presence of PF4/heparin antibody 
should be demonstrated using immunological or functional 
assay, especially in patients with high scores using Warken-
tin’s scoring system [1, 7-10]. Although they are regarded 
as more precise tests than the immunologic assay, functional 
assays such as SRA or HIPA are difficult to perform and 
require experienced laboratory technicians. Therefore, eval-Korean J Hematol 2012;47:39-43.
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Table 4. Comparison of platelet count, PT, aPTT, fibrinogen, D-dimer, and DIC scores between patients with and without anti-PF4/heparin 
antibodies.
Anti-PF4/
heparin 
antibody
No. of 
patients
Variables, median (range)
Overt DIC (%)
P=0.506
b) Platelet (×10
9/L)
P=0.460
a)
PT (sec)
P=0.853
a)
aPTT (sec)
P=0.789
a)
Fibrinogen (g/L)
P=0.142
a)
D-dimer (μg/L)
P=0.016
a)
DIC score
P=0.495
a)
Negative
c)  107 56.0 15.2 40.7 2.62  4,170 4.0  46/107 
(5.0-366.0) (10.0-42.0) (26.3-546.0) (0.04-8.79)   (180-55,700) (0.0-8.0) (43.0)
Positive
c) 20 62.5 14.4 42.1 2.00  2,450 3.5 7/20 
(4.0-276.0) (11.2-45.3) (25.4-180.0) (0.30-4.15) (160-5,310) (0.0-7.0) (35.0)
Total 127 59.0 15.0 41.1 2.57 3,800 4.0 53/127 
(4.0-366.0) (10.0-45.3) (25.4-546.0) (0.04-8.49)   (160-55,700) (0.0-8.0) (41.7)
P-values obtained from Mann-Whitney U test
a) and Chi-Square test
b).
c)Anti-PF4/heparin antibody was defined as negative when all the results of the 2 assays were within the Cutoff values (optical density of 0.304 
for Asserachrom HPIA and 1U/mL for HemosIL HIT-Ab based on the manufacturer’s recommendations) and was defined as positive when at 
least one of the 2 results was beyond the cutoff values.
Abbreviations: PT, prothrombin time; aPTT, activated partial prothrombin time; DIC, disseminated intravascular coagulation; PF4, platelet factor 4.
uation of serum PF4/heparin antibody levels using immuno-
assay is proposed as a practical and useful adjunct in clinical 
settings, because immunoassay permits high throughput 
within a limited time.
Previous studies have reported that PF4/heparin antibody 
testing is a reliable strategy to rule out the diagnosis of 
HIT when combined with the Warkentin 4T’s scoring system 
results. However, the risk of false positivity in PF4/heparin 
antibody testing limits its efficacy. Therefore, a functional 
assay such as SRA or HIPA is thought to be necessary to 
confirm HIT in antibody positive patients [1, 14, 15]. In 
our study, because the Warkentin 4T’s scoring system was 
only applied to patients in the study population who were 
antibody positive, the confirmation of the usefulness of the 
PF4/heparin antibody test may be limited. However, our 
results have demonstrated that more than a half of the pa-
tients with antibody in at least 1 of 2 assays had a clinically 
“same or more than IR” of HIT. This implies that in some 
cases, PF4/heparin antibody tests may be useful not only 
for the exclusion, but also for the diagnosis of HIT.
The seropositivity of PF4/heparin antibody can vary ac-
cording to the clinical settings. Previous studies have reported 
seropositivity rates of 14.3% and 13.6% in 755 heparinized 
patients and 59 ICU patients undergoing heparin prophylaxis, 
respectively. In the latter result, the clinical setting was 
same as that in our study [14, 15]. In Korea, a study on 
338 patients with acute coronary syndrome receiving un-
fractionated heparin reported an incidence of HIT as 11.8% 
[16]. However, this study diagnosed HIT based on clinical 
information, not on the immunological detection of 
PF4/heparin antibody. As previously mentioned, to date, 
no studies, other than case reports, regarding seropositivity 
of PF4/heparin antibody using immunoassay have been 
published. [17, 18]. Our study analyzed seropositivity of 
PF4/heparin antibody in 127 ICU patients who were receiv-
ing heparin by 2 kinds of immunoassays. Our results demon-
strated a seropositivity rate for PF4/heparin antibody of 
8.7-11.0%, which is similar to the finding of 13.6% in the 
previous study performed in same clinical setting mentioned 
above [14]. Our study is the first study, which evaluated 
the seropositivity of PF4/heparin antibody in ICU patients 
in Korea.
If an ICU patient receiving heparin develops both throm-
bocytopenia and clinical signs of thrombosis, the most im-
portant aspect to provide appropriate management is the 
differentiation between DIC and  H I T .  B o t h  h a v e  s i m i l a r  
clinical profiles, but require totally different therapeutic 
approaches. Currently, many clinicians evaluate patients for 
DIC using coagulation tests such as PT/aPTT, fibrinogen, 
and D-dimer and subsequently calculating the DIC score 
suggested by ISTH 2001 criteria [13]. Our results showed 
that only D-dimer was significantly different between pa-
tients with antibody and those without antibody. This in-
dicates that the most commonly performed coagulation tests 
are of limited value for differentiating between DIC and 
HIT. Therefore, it is proposed that the PF4/heparin antibody 
test should be performed for the diagnosis of HIT in thrombo-
cytopenic ICU patients receiving heparin. 
There are limitations in our study. First, as mentioned, 
we did not evaluate the clinical possibility of HIT for all 
the patients using the 4T’s system. This may have influenced 
our evaluation on the usefulness of the PF4/heparin antibody 
test. Second, we did not compare PF4/heparin antibody test 
results with results from standard methods such as SRA 
or HIPA due to technical reasons. Further studies eliminating 
these limitations should be required in the future. 
In conclusion, the seropositivity for anti-PF4/heparin anti-
body was 8.7-11.0% in heparin-treated ICU patients with 
thrombocytopenia, and more than a half of them had in-
creased probability of HIT by 4Ts score. Among the routine 
coagulation tests, only D-dimer was informative for discrim-
inating HIT from DIC. Anti-PF4/heparin antibody test 
should be performed in thrombocytopenic ICU patients re-
ceiving heparin in order to provide the appropriate treat-
ment.Korean J Hematol 2012;47:39-43.
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